Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 m ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry ...

Cybin (NYSE Americ a n: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced that CEO Doug Drysdale will join a fireside chat at th ...

The popularity of psilocybin is fast-rising, with an estimated 8 million American adults using it in 2023.  The percentage of US adults who have used psilocybin at least once in their lifetime, ...

Recently, a team of researchers has made a significant discovery that could transform the way pain relief is approached. According to an article published in SciTechDaily, scientis ...

SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...

NUS researchers found that deuterated water (D₂O) reduces pain by modulating the TRPV1 ion channel, offering a non-addictive alternative to conventional painkillers. Researchers from the (NUS), in ...

Deuterated etifoxine is under clinical development by GABA Therapeutics and currently in Phase I for Social Anxiety Disorder (SAD/Social Phobia). According to GlobalData, Phase I drugs for Social ...

and deuterated water (D₂O). This advanced technology enabled real-time tracking of water dynamics at both the single-cell and single-molecule levels. The study showed that when D₂O passed ...

Designed for the analysis of chemical processes by NMR, InsightMR is the ideal solution for both industrial and academic scientists studying or optimizing reactions. InsightMR’s two components ...

The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary ...

北京时间2024年12月03日02时04分，Atai Life Sciences N.V.（ATAI.us）股票出现波动，股价快速下跌5.62%。截至发稿，该股报1.68美元/股 ...